Guidance (a Joint Ministerial Decision) addresses the offsets of “clawback amounts” against expenses related to research and development (R&D) and investment projects.
The guidance establishes the terms and conditions as well as the procedure for offsetting of clawback amounts payable to the Greek National Health Service Organization (GNHSO) and hospitals, against R&D and investment projects for the development of products, services or production lines incurred by pharmaceutical companies.
Activities that qualify as R&D projects relate to the marketing of a pharmaceutical product, and can include:
Eligible expenses related to R&D projects therefore may include:
An investment project related to the development of products, services or production is considered any activity aiming for the establishment of new facilities or the modernization of the existing ones, aiming to improve the quality of the products and of the existing production methods, and/or aiming to increase the dynamics of the production procedures.
Eligible expenses related to investment projects may include:
Especially for 2019, eligible expenses are considered those effected as of 1 July 2019 assuming the relevant contracts were signed as of 1 January 2019.
The documentation file and relevant supporting documentation must be submitted to the GSRT within four months after the end of the applicable tax year.
Read a February 2020 report prepared by the KPMG member firm in Greece
The KPMG logo and name are trademarks of KPMG International. KPMG International is a Swiss cooperative that serves as a coordinating entity for a network of independent member firms. KPMG International provides no audit or other client services. Such services are provided solely by member firms in their respective geographic areas. KPMG International and its member firms are legally distinct and separate entities. They are not and nothing contained herein shall be construed to place these entities in the relationship of parents, subsidiaries, agents, partners, or joint venturers. No member firm has any authority (actual, apparent, implied or otherwise) to obligate or bind KPMG International or any member firm in any manner whatsoever. The information contained in herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.